AUG 2 5 2005

PATENTS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Hembrough et al.)) Art Unit: 1614
Serial No. 10/608,886) Alt Ollit: 1014
Filed: June 26, 2003)
For: Compositions and Methods Comprising Protein Activated Receptor Antagonists))

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of the listed items is enclosed.

Certificate

It is hereby certified, under Rule 97(e)(1), that each item of information contained in the accompanying Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 23rd day of August, 2005.

S. Lynn Freeman-Rees - Paralegal

ATLLIB02 190612.1

U.S. Application No: 10/608,886 Supplemental Information Disclosure Statement

not more than three months prior to the filing of the statement. A copy of the European Search Report is also attached.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Thisley & Brosnice

By: Shirley E. Brosmore

Reg. No. 56,167

KILPATRICK STOCKTON LLP 1100 Peachtree Street Suite 2800 Atlanta Georgia 30309-4530

Atlanta, Georgia 30309-4530

(404) 815-6500

Our Docket: 05213-3041 (43170-286877)

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under th	he Pape	work Re	duction Aet of 1	95 pro persons	are required to re	espond to a collection	n of informatio	n unless	it contains a valid OMB contro	l num	
Substitute for Form 1449/A/PTD						Complete if Known					
					Application No.		10/6	0/608,886			
AUG 2 5 2005						Filing Date		06/2	06/26/2003		
INFORMATEON DISCLOSURE						First Named Inventor H		Hem	mbrough		
S	STATEMENT BY ARPLICANT (use as many sheets as necessary)				Group Art Unit 16		1614	14			
						Examiner Name U		Una	Unassigned		
Sheet	Sheet 1 of 2		Attorney Dock	cket Number 05213-3041 (43170-286877)		13-3041 (43170-286877)					
	•			FO	REIGN PAT	ENT DOCUME	INTS				
Examiner Initials	Cite No.1	Office'	Foreign Patent Do		4 1		Date of Publ of Cited Doo MM-DD-Y	ument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°	
	1	WO	03/082231	A2	Johnson & Johnson Consumer Companies, Inc.		10/09/20	003			
	2	wo	03/099841	A2	Johnson & John Companies, Inc		12/04/20	003			

		T
Examiner	Date	
·	Dute	
Signature	Considered	

^{&#}x27;Unique citation designation number. 'See attached Kinds of U.S. Patent Documents. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act 1995, Experience are required to respond to a collection of information unless it contains a valid OMB control number

			/	<u> </u>		Complete	if Known		\neg
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application N	0.	10/608,886				
			Filing Date		06/26/2003				
			First Named I	nventor	Hembrough				
			Group Art Ur	it	1614				
(use as many sheets as necessary)				Examiner Nar	ne	Unassigned			
Sheet		2 0	of 2		Attorney Dock	et Number	05213-3041 (43170-286877)		
	- 1					<u> </u>			\dashv
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS									
	Г	1							\dashv
Examiner	Cite				LETTERS), title of the article (when appropriate), title of the aposium, catalog, etc.), date, page(s), volume-issue number(s),			T° ∤	
Initials No. No. No. Publisher, city and/or country where published									
	3 Author: AL-ANI et al. Title: Modified Proteinase-Activated Receptor-1 and -2 Derived Peptides Inhibit								
	Proteinase-Activated Receptor-2 Activation by Trypson Publ:								1 1
	The Journal of Pharmacology and Experimental							ł I	
	Therapeutics Vol/Iss: 300 (2) Pages: 702-708 Date: 02/2002								
	4 Author: HAWTHORNE et al. Title: Antagonists of PAR2 on Human Skin Keratinocytes Identified Using a Microtitre Plate-Based Calcium Mobilisation Assay (Abstract Only)						1 1		
		Publ:					,,		
			nal Symposium						
		Peptides, Cairs,	Queensland, A	utralia Vol/Iss	: 94 (1-3)	Pages:	Date:	10/25/2000	

Examiner	Date	
Signature	Considered	